KP-736, a new cephem antibiotic with a broad antibacterial spectrum and potent antipseudomonal activity, was evaluated for in vitro antibacterial activity in comparison with ceftazidime, cefotaxime, and cefpirome. KP-736 was significantly more active than the test compounds against gram-negative bacteria, including the Pseudomonas group and ceftazidime-, cefotaxime-, or imipenem-resistant strains, but less active against gram-positive bacteria. KP-736 had very high affinities for penicillin-binding protein 3 (PBP 3) of Escherichia coli K-12 and PBP 1A and PBP 3 of Pseudomonas aeruginosa NCTC 10490 and showed potent bactericidal activities against these two strains. It was stable to hydrolysis by penicillinases and cephalosporinases but was slightly hydrolyzed by oxyiminocephalosporinases and type II penicillinase.
Recently, several P-lactam antibiotics containing catechol derivatives in the structure have been reported to possess excellent antibacterial activity against P. aeruginosa (1, 3, 6, 10, 11, 13, 14, 16) .
KP-736, disodium (6R,7R)-7-[(z)-2-(2-aminothiazole-4-yl)-
2-(1,5-dihydroxy-4-pyridon-2-ylmethoxyimino)acetamidol-3-(1,2,3-thiadiazole-5-ylthiomethyl)-3-cephem-4-carboxylate ( Fig. 1) , is a new cephem with a broad antibacterial spectrum and potent antipseudomonal activity, synthesized at Kaken Pharmaceutical Co., Ltd., Tokyo, Japan. In this paper, we report the in vitro activity of KP-736 in comparison with that of ceftazidime (24) , cefotaxime (8) , and cefpirome (5) against gram-positive and gram-negative clinical isolates including strains resistant to ceftazidime, cefotaxime, or imipenem. In addition, binding affinity for the target, penicillin-binding proteins (PBPs) , and stability against hydrolysis by ,-lactamases are presented.
(This work was presented in part at the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Tex., 17 to 20 September 1989 [abstr. no. 482].)
MATERIALS AND METHODS
Antibiotics. KP-736 was synthesized at the Central Research Laboratories, Kaken Pharmaceutical Co., Ltd. Other compounds were obtained as follows: ceftazidime and cephaloridine, Nihon Glaxo, Co., Tokyo, Japan; cefotaxime and cefpirome, Hoechst Japan, Co., Tokyo, Japan; cefoxitin, Daiichi Pharmaceutical Co., Tokyo, Japan; imipenem, Banyu Pharmaceutical Co., Tokyo, Japan; and penicillin G, Meiji Seika Kaisha, Ltd., Tokyo, Japan.
Organisms. Bacterial strains used in this study were recent clinical isolates collected from various laboratories and hospitals in Japan. All isolates were maintained as stock cultures at the Episome Institute. Imipenem-resistant P.
* Corresponding author. aeruginosa strains were collected independently of the other strains.
Determination of MICs. MICs were determined by the twofold agar dilution method with sensitivity disk agar-N (SDA-N; Nissui Pharmaceutical Co., Ltd., Tokyo, Japan), which is modified Mueller-Hinton agar, unless otherwise specified, as previously described (7) . The overnight broth cultures of the bacterial strains were diluted with corresponding broth or buffered saline containing 0.01% gelatin to a final concentration of about 5 x 106 CFU/ml. Then 5 ,ul of each bacterial suspension, corresponding to about 104 CFU, was spotted with an inoculator (Microplanter; Sakuma Seisakusho, Tokyo, Japan) onto an agar plate containing twofold serial dilutions of antibiotics. The inoculated plates were incubated for 18 h at 37°C, except for those containing Haemophilus influenzae and Neisseria gonorrhoeae, which were incubated in a candle extinction jar for 18 h, and those containing anaerobes, which were incubated in an anaerobic chamber for 24 h. The MIC was defined as the lowest concentration of the compound that prevented visible growth on the agar plate. MICs were also determined by the twofold broth dilution method. Each 1-ml portion containing a serial dilution of the compounds in sensitivity test broth (STB; Nissui) was inoculated with overnight cultures in STB at 37°C to yield a final inoculum about 106 CFU/ml. The tubes were incubated for 18 h at 37'C. The Time-kill study. The mid-logarithmic-phase cells (approximately 106 CFU/ml) were exposed to antibiotics at a concentration of 1/4, 1/2, 1, 2, or 4 MICs. Two 50-,lI samples were removed at fixed times, and several 10-fold dilutions were prepared in saline if needed and plated onto antibioticfree SDA-N (10 ml per plate). Drug carryover was reduced by a 200-fold dilution of the sample with agar and did not affect colony formation. The number of colonies was counted after a 24-h incubation at 37°C. We could detect viable cells above 20 CFU/ml by this procedure. The MICs of KP-736 and ceftazidime were 0.39 and 0.20 ,ug/ml, respectively, against E. coli K-12 strain C600 and 0.39 and 1.56 ,ug/ml, respectively, against P. aeruginosa NCTC 10490 by the broth dilution method.
Assay of affinity for PBPs. The affinity for PBPs was determined by the conventional competition assay with [14C]penicillin G (Amersham Japan Co., Ltd., Tokyo, Japan) as described previously (20) with some modifications (21) . Membrane proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by fluorography. The relative band densities on the fluorogram were determined by using a scanning densitometer (Densitron PAN-802; Jookoo, Tokyo, Japan). The binding affinities of antibiotics for each PBP were expressed in terms of the concentration required to prevent ['4C]penicillin G binding by 50%.
Stability to ,-lactamase. The various types of P-lactamase used in this study were totally or partially purified enzymes.
The stability of the antibiotics to P-lactamase was determined by the spectrophotometric assay (22) . The molecular absorbancy difference (Ar,) and the specific wavelength for KP-736 were 6.65/mM/cm and 272.7 nm, respectively. The relative rate of hydrolysis was determined as the initial rate at 100 F.M each compound.
RESULTS
Antibacterial activity. The in vitro activities of KP-736, ceftazidime, cefotaxime, and cefpirome against gram-positive and gram-negative bacteria are summarized in Table 1 1.56 ,ug/ml, respectively, although reference compounds CFU/ml, respectively. Time-kill studies were carried out at inhibited 90% of the organisms at the concentrations.
about 106 CFU/ml, which was a slightly larger inoculum than The most characteristic activity of KP-736 is its superior that for the MIC determination. KP-736 was bactericidal activity against Pseudomonas spp. Its MIC50 for P. aerugiagainst E. coli even at 1/4 MIC for 4 h, whereas ceftazidime nosa was 0.39 ,ug/ml, its activity was four-to eightfold higher failed to reduce the number of CFU at 1/4 MIC. In addition, than that of ceftazidime, and its MIC90 was equal to the there was an evident difference in bactericidal activity M'C50 of cefpirome, 12.5 ,ug/ml. The MIC90 of KP-736 for between KP-736 and ceftazidime at concentrations higher imipenem-resistant P. aeruginosa was identical to that for than the MICs. There was no significant difference in the 281 susceptible strains, although the MIC50 for the resistant reduction in the number of cells of these two strains by strains was fourfold higher than that for the susceptible ceftazidime. On the other hand, KP-736 expressed equally strains. Furthermore, Pseudomonas cepacia was surprispotent bactericidal activity against P. aeruginosa at every ingly susceptible to KP-736, which had an MIC90 of 0.39 dose tested; 1/4 MIC of KP-736 was enough to reduce the ,ug/ml, although 0.39 ,ug of control drugs per ml failed to CFU by 3 logs in 4 h.
inhibit 50% of the strains. KP-736 was also highly active Affinity for PBPs. The affinities of KP-736 for PBPs of E. against Xanthomonas maltophilia, with an MIC50 of 1.56 coli K-12 strain C600 and P. aeruginosa NCTC 10490 were ,ug/ml, while reference compounds had lower activity against estimated by the conventional competition assay with the strain. Cefotaxime was the least active compound tested ['4C]penicillin G ( Table 2 ). KP-736 had very high affinities against the Pseudomonas group.
for PBP 3 of E. coli and PBP 1A and PBP 3 of P. aeruginosa, Time-kill study. The bactericidal activities of KP-736 were as did cefotaxime. The affinities of the test compounds for compared with those of ceftazidime against E. coli K-12 PBP 5/6 of E. coli and PBP 5 of P. aeruginosa were poor. strain C600 and P. aeruginosa NCTC 10490 (Fig. 2) 1, 3, 6, 10, 11, 13, 14, 16 ). Some of these compounds, such as E-0702 (23), M14659 (12) , and pirazmonam (2), have been reported to chelate iron and have been suggested to be incorporated into bacterial cells via the tonB-dependent iron transport system. It has been demonstrated that KP-736 similarly chelates iron and exhibits strong activities against laboratory mutants of P. aeruginosa with an altered outer membrane, and it was suggested that the compound was incorporated into the cells of P. aeruginosa not only through the porin but also by the iron transport proteins (25) . This feature enables us to understand the excellent activity of KP-736 mentioned above.
Mitsuhashi et al. have proposed the classification of a group of enzymes, CXases, in terms of substrate specificity and have divided them into two subgroups, types I and II, by substrate and inhibitor profiles (9) . The potent activities of KP-736 were also effective against bacteria that produce CXases, such as K. oxytoca, Proteus vulgaris, Pseudomonas cepacia, and Xanthomonas maltophilia, although KP-736 was hydrolyzed by the enzymes from these species to some extent. This also suggests that hydrolysis of KP-736 by the enzymes is overcome by rapid supply of the drug resulting from the special penetration or by high binding affinity to the target, PBPs. KP-736 is stable to hydrolysis by penicillinases and cephalosporinases; this stability is comparable to that of cefotaxime. This characteristic may also raise the activity of KP-736 against gram-negative clinical isolates that produce chromosome-or plasmid-mediated P-lactamase.
Since KP-736 has strong activity against clinical isolates, including strains resistant to imipenem, we consider that KP-736 is a very promising parenteral cephalosporin for the treatment of serious infection caused by gram-negative bacteria.
